Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 6, 2022Russian Journal of CardiologyOpen Access

High-sensitivity troponin I as a predictor of left ventricular dysfunction in the use of cardiotoxic anticancer agents for breast cancer in patients with predominantly low and moderate risk of cardiotoxicity

View Full Paper
Ask AI
Bookmark
Share

Why the study?

The study evaluated the significance of monitoring hs-cTnI for predicting anthracycline-induced LV dysfunction in breast cancer patients with moderate and low cardiotoxicity risk.

Does monitoring high-sensitivity troponin I predict anthracycline-induced left ventricular dysfunction in breast cancer patients with low to moderate risk of cardiotoxicity?

Population

49 breast cancer patients aged 50±10 years receiving doxorubicin-based chemotherapy

Comparison

Monitoring hs-cTnI before and during anthracycline chemotherapy

Follow-up

12 months after the end of anthracycline therapy

Authors

VLV. D. LevinaSechenov UniversityMPM. G. PoltavskayaSechenov UniversityPCP. Sh. ChomakhidzeSechenov University

Discussion

Loading...

Member takes

Overview

hs-cTnI before and after third anthracycline course was associated with cardiotoxicity; leaves open whether monitoring improves outcomes in low-moderate risk patients.

Structured PICO

Does monitoring high-sensitivity troponin I predict anthracycline-induced left ventricular dysfunction in breast cancer patients with low to moderate risk of cardiotoxicity?

P
Population
49 patients with breast cancer aged 50±10 years undergoing neoadjuvant or adjuvant chemotherapy including doxorubicin (course dose 60 mg/m2, average cumulative dose 251±60 mg/m2), with 96% having low and moderate risk of cardiotoxicity before chemotherapy.
I
Intervention
Monitoring of high-sensitivity troponin I (hs-cTnI) before chemotherapy and after each course of anthracyclines.
O
Outcome
Cardiotoxicity defined as a decrease in LV ejection fraction (EF) by ≥10% to <53% measured by echocardiography every 3 months for 12 months after anthracycline therapy.surrogate

Monitoring high-sensitivity troponin I before and during anthracycline therapy predicts the development of left ventricular dysfunction even in breast cancer patients with low to moderate baseline risk.

Cite This Study

Levina et al. (2022) studied this question.

synapsesocial.com/papers/6a816930d433ecbb06e1c8e7https://doi.org/10.15829/1560-4071-2022-5210
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury2016 · 47 citations
  2. 2Elevations in High-Sensitive Cardiac Troponin T and N-Terminal Prohormone Brain Natriuretic Peptide Levels in the Serum Can Predict the Development of Anthracycline-Induced Cardiomyopathy2019 · 22 citations
  3. 3Troponins and Brain Natriuretic Peptides for the Prediction of Cardiotoxicity in Cancer Patients: A Meta-Analysis2019 · 265 citations
  4. 4Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy2017 · 95 citations
  5. 5Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology2020 · 360 citations